Expert meeting report reviews pharmacological strategies for acquired hypothalamic obesity
Could new drugs help patients with hypothalamic obesity finally control their hunger and lose weight?
An expert meeting report from Frankfurt am Main, Germany, discussed pharmacological strategies including dextroamphetamine, glucagon-like pe…
New drugs targeting hunger pathways show promise for patients with hypothalamic obesity, offering hope where diets and exercise have failed …
GLP-1RA use shows sex-specific pancreatitis and hypotension risks in T2D second-line therapy study
Diabetes drugs work differently in women than men
A retrospective cohort study of 5.15 million adults with type 2 diabetes compared second-line therapies. Women initiating GLP-1RAs had highe…
Diabetes drugs work differently for women than men, revealing distinct safety and effectiveness outcomes in a massive study of 5 million adu…
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes
Observational study links GLP-1 RA to lower risk than SGLT2i in heart failure patients
An observational study using real-world EHR data from Stony Brook University Hospital compared GLP-1 RAs to SGLT2 inhibitors in patients wit…
In heart failure patients, GLP-1 receptor agonists showed a lower risk of death or hospitalization compared to SGLT2 inhibitors over one yea…